Table 2 SNOT-22 outcomes
Baseline SNOT-22 | SNOT-22 1-month post-dupilumab | Change in SNOT-22 1-month post-dupilumab | SNOT-22 3 months post-dupilumab | Change in SNOT-22 3-months post-dupilumab | SNOT-22 6 months post-dupilumab | Change in SNOT-22 6-months post-dupilumab | SNOT-22 12 months post-dupilumab | Change in SNOT-22 12-months post-dupilumab | |
|---|---|---|---|---|---|---|---|---|---|
Total cohort (Mean ± SD) | 60.6 ± 18.8 | 56.8 ± 37.4 | − 8.8 ± 10.5 | 40.4 ± 16.8 | − 26.5 ± 14.0 | 26.1 ± 22.0 | − 42.8 ± 24.6 | 26.1 ± 17.9 | − 33.8 ± 26.3 |
AERD (Mean ± SD) | 56.5 ± 14.4 | 24 ± 33.9 | − 5.5 ± 7.8 | 31.3 ± 22.2 | − 28.3 ± 16.2 | 27.4 ± 21.8 | − 40.3 ± 29.0 | 15.2 ± 17.8 | − 46.0 ± 18.9 |